PBLS (Parabilis Medicines) Deferred Tax: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $38.85
! 2 Warning Signs
View Full Analysis

What is Parabilis Medicines Deferred Tax?

Parabilis Medicines PBLS -2.71% 10 Deferred Tax is $0.00 Mil as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Parabilis Medicines's change in deferred tax for the six months ended in Dec. 2025 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Parabilis Medicines Deferred Tax Related Terms

Parabilis Medicines Deferred Tax Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Deferred Tax Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Deferred Tax
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Deferred Tax 0.00 0.00
PBLS
10GF Score
Parabilis Medicines Inc PBLS
Deferred Tax is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Deferred Tax →
What does a Deferred Tax of $0.00 Mil mean?
Parabilis Medicines (PBLS) has a Deferred Tax of $0.00 Mil as of Dec. 2025. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Parabilis Medicines.
Is Parabilis Medicines' Deferred Tax too high?
Parabilis Medicines' current Deferred Tax is $0.00 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Deferred Tax compare to DYN and ACAD?
Parabilis Medicines' Deferred Tax of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Deferred Tax for a Biotechnology company?
A good Deferred Tax depends on the Biotechnology industry context. However, Deferred Tax should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Deferred Tax mean?
A high Deferred Tax can signal that a stock is expensive relative to its fundamentals. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Parabilis Medicines. Parabilis Medicines's current Deferred Tax is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Deferred Tax of $0.00 Mil. The current Deferred Tax is $0.00 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Deferred Tax calculated?
Deferred Tax is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Deferred Tax is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Deferred Tax is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.85
Price